Webcasts

The pathologist's impact on clinical practice & patients' lives

Hear Prof. Giancarlo Pruneri of the University of Milan providing his insights on the importance of analytical work and the critical need to integrate multigene assays (MGAs) into a laboratory routine, as well as explain how this can be done.

The development of the Oncotype DX Breast Recurrence Score^® test in breast cancer

Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the analytical validation and the key clinical attributes of the the Oncotype DX^® test.

Clinical validation of the Oncotype DX Breast Recurrence Score^® test in breast cancer

Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the clinical validation of the Oncotype DX^® test in TAILORx (N0 population) and RxPONDER (N1 population).

Future of the Oncotype DX Breast Recurrence Score^® test in breast cancer

Rick Baehner, MD - Exact Science’s Chief Medical Officer, presents on the Oncotype DX^® test in ongoing trials.

Improve patient care with genomic testing to tailor adjuvant systemic treatment in early HR+, HER2- breast cancer

Hybrid Satellite Symposium with Prof. Valentina Guarneri (Italy), Prof. Christos Markopoulos (Greece) and Prof. Richard Simcock (UK) at the St. Gallen International Breast Cancer Conference on the 15 March 2023 in Vienna, Austria.

Personalize adjuvant systemic treatment with genomic testing in early-stage HR+, HER2- breast cancer

Satellite Symposium with Prof. David Cameron (UK), Prof. Miguel Martín (Spain) and Prof. Joseph Gligorov (France). Thursday, 17 November 2022 at the European Breast Cancer Conference.

ECP 2022: Genomic testing to guide treatment decisions in HR+, HER2- early breast cancer

Prof. Cecily Quinn from the St. Vincent’s University Hospital in Dublin presents what is new in Oncotye DX Breast Recurrence Score^® testing.

Advancing precision oncology with genomic testing in early-stage HR+, HER2- breast cancer

What evidence do we have to guide treatment decisions with genomic testing in early-stage HR+, HER2- breast cancer? Genomic testing in early-stage HR+, HER2- breast cancer – when and whom?

Guiding N1 treatment decisions after RxPONDER

Prof. Catherine Kelly from the Trinity St James Cancer Institute in Dublin presents the RxPONDER results.

Initial RxPONDER results in clinical practice: What will change?

Dr. Joan Albanell from the Hospital del Mar, Spain and and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial RxPONDER results presented at SABCS 2020 and what impact this has on the clinical practice.

Initial RxPONDER results in clinical practice: What will change?

Prof. Stephen Chia from the University of British Columbia, Canada and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial RxPONDER results presented at SABCS 2020 and what impact this has on the clinical practice.

Clinical practice revisited: Improving chemotherapy treatment decisions in early-stage breast cancer

Prof. Hartkopf from the University of Tuebingen talks about the evidence from his clinical practice and which parameters guide treatment decisions in early-stage breast cancer. Prof. Thill form Agaplesion Markus Hospital discusses real-world evidence from the REMAR study and how treatment decisions are optimized with multigene testing.

Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy

Watch an expert panel at the 2019 St. Gallen International Breast Cancer Conference discuss evidence on how to guide adjuvant chemotherapy treatment decisions in HER2-, HR+, early-stage breast cancer patients.

The Oncotype DX Breast Recurrence Score^® assay in clinical practice

Prof. Maccon Keane from the Saolta University Health care Group at the University Hospital Galway in Ireland discusses the Oncotype DX Breast Recurrence Score^® assay evidence and in particular, the TAILORx landmark trial data.